Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rödel, C.
Right arrow Articles by Meyer, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Rödel, C.
Right arrow Articles by Meyer, M.
Related Articles
Right arrowRelated Article
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
Journal of Clinical Oncology, Vol 21, Issue 15 (August), 2003: 3003-3004
© 2003 American Society for Clinical Oncology


CORRESPONDENCE

In Reply:

Claus Rödel1, Martin Meyer2

1 University of Erlangen, Erlangen, Germany
2 Population Based Cancer Registry, Bavaria, Germany

We would like to thank Dr Goel for carefully reading our article1 and commenting on some missing statistical information. Indeed there is a typing error in Figure 1 of our article: The number of patients who received salvage treatment categorized as "other" did not add up to 16 patients, as erroneously cited in the figure, but to only 11 patients. We would like to apologize for this error.

We do not agree, however, to exclude the 17 patients who did not undergo restaging transurethral resection (TUR) from the denominator when calculating the percentage of salvage cystectomy applied for tumor progression or relapse. Although we do not have information with respect to the immediate tumor response for these 17 patients, we do have follow-up data. None of these 17 patients were treated with salvage cystectomy during the follow-up period. Thus the percentage of patients among the entire group that underwent salvage cystectomy remains 83 (20%) of 415 patients. This does not imply, however, that these 17 patients did not experience a local relapse or local tumor progression, but simply indicates that cystectomy was not a treatment option in these patients, mainly because of advanced age or patient refusal.

The most important point raised by Dr Goel refers to the problem of multicollinearity. Of course T stage, N stage, and R status of residual tumor after TUR (R0, R1, R2) are not completely independent variables, statistically or clinically. For T4 tumors we observed some more nodal positive cases (as judged clinically by computed tomography scan, not histopathologically in the resected specimen) than for T1 to T3 tumors, but this difference was not significant. On the other hand, there was an association between the degree of residual tumor and T stage as well as between R stage and N stage, but the calculated values of r2 (Spearmen correlation) did not indicate a risk of multicollinearity (T stage v R status, r2 = 0.14; N stage v R status, r2 = 0.02).

Candidates for joining the multivariate model as independent variables were selected using the results of univariate analysis. All selected variables were included in the regression model (no stepwise method). The differences in the significance of the three factors (T stage, N stage, R status) in the multivariate models might reflect their unequal clinical impact on the respective end points. For the end point of complete response at restaging TUR, it is obvious that the degree of residual tumor before radiotherapy or radiochemotherapy had the strongest impact, as it is very unlikely that a patient with a complete initial TUR (R0) will have residual tumor at restaging TUR 6 weeks after completion of radiotherapy or radiochemotherapy. The risk of developing distant metastases is biologically highest among patients with advanced disease (T3/4 or N+), whereas the variable R status also reflects some treatment-related constraints (eg, quality of surgery, topography of tumor site, irresectability of superficial but large tumors) that are not directly related to the risk of developing distant disease.

REFERENCE

1. Rodel C, Grabenbauer GG, Kuhn R, et al: Combined-modality treatment and selective organ preservation in invasive bladder cancer: Long-term results. J Clin Oncol 20:3061–3071, 2002[Abstract/Free Full Text]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Article

  • Alternatives to Cystectomy in Muscle-Invasive Bladder Cancer
    Sanjay Goel
    JCO 2003 21: 3003 [Full Text]



This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rödel, C.
Right arrow Articles by Meyer, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Rödel, C.
Right arrow Articles by Meyer, M.
Related Articles
Right arrowRelated Article
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2003 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online